Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Reinforcing commitment to ethical and sustainable growth
AINU is set to accelerate its expansion footprint, enhance operational capabilities
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Subscribe To Our Newsletter & Stay Updated